VA2009 SESSIONS |
|
04/10/2009
LIONEL ROOM
08.30 - 10.30
Atrial Fibrillation 2009 revisited - AF: EPIDEMIOLOGY AND CLINICAL ASPECTS
Atrial Fibrillation 2009 revisited - AF: EPIDEMIOLOGY AND CLINICAL ASPECTS
S.C. Hammill
AF: extension of the problem and socio-economic impact
AF: extension of the problem and socio-economic impact
G. Breithardt
Asymptomatic AF: how frequent is it, how to detect it, and which clinical significance?
Asymptomatic AF: how frequent is it, how to detect it, and which clinical significance?
A.S. Montenero
Lone AF: what is the cause and the prognosis?
Lone AF: what is the cause and the prognosis?
W.G. Stevenson
AF and heart failure: which relationship?
AF and heart failure: which relationship?
J. Almendral
AF-induced tachycardiomyopathy: how to diagnose and treat it?
AF-induced tachycardiomyopathy: how to diagnose and treat it?
11.00 - 13.00
Atrial Fibrillation 2009 revisited - AF: NEW RISK FACTORS
Atrial Fibrillation 2009 revisited - AF: NEW RISK FACTORS
M. Scheinman
Genetic predisposition
Genetic predisposition
H.V. Huikuri
Inflammation
Inflammation
G. Zuin
Alcohol, coffee, tea and drugs
Alcohol, coffee, tea and drugs
M. Di Biase
Obesity
Obesity
I.C. Van Gelder
Obstructive sleep apnoea
Obstructive sleep apnoea
14.30 - 16.30
Atrial Fibrillation 2009 revisited - CARDIOVERSION OF AF: 2009 UPDATE
Atrial Fibrillation 2009 revisited - CARDIOVERSION OF AF: 2009 UPDATE
D. Roy
Pharmacological cardioversion: when and how?
Pharmacological cardioversion: when and how?
G.L. Botto
Pill-in-the-pocket approach in patients on chronic drug prophylaxis: how safe is it?
Pill-in-the-pocket approach in patients on chronic drug prophylaxis: how safe is it?
N. Baldi
Pre-treatment with AADS: for whom and with which drug?
Pre-treatment with AADS: for whom and with which drug?
M.E. Cain
Repeat electrical cardioversion: how many attempts are justifi ed, today, in the era of catheter ablation?
Repeat electrical cardioversion: how many attempts are justifi ed, today, in the era of catheter ablation?
G.V. Naccarelli
Predictors of successful cardioversion and sinus rhythm maintenance
Predictors of successful cardioversion and sinus rhythm maintenance
05/10/2009
LIONEL ROOM
08.30 - 10.30
Atrial Fibrillation 2009 revisited - MANAGEMENT OF AF IN DIFFERENT CLINICAL SETTINGS
Atrial Fibrillation 2009 revisited - MANAGEMENT OF AF IN DIFFERENT CLINICAL SETTINGS
A.L. Waldo
Elderly
Elderly
J. Brachmann
Hypertension
Hypertension
F. Lombardi
Coronary artery disease
Coronary artery disease
A.J. Camm
Heart failure
Heart failure
F. Gaita
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy
11.00 - 13.00
Atrial Fibrillation 2009 revisited - PREVENTION OF AF: ANTIARRHYTHMIC AND NON-ANTIARRHYTHMIC DRUGS
Atrial Fibrillation 2009 revisited - PREVENTION OF AF: ANTIARRHYTHMIC AND NON-ANTIARRHYTHMIC DRUGS
F. Naccarella
Drug resistant AF: is the combination of AADs a valid option?
Drug resistant AF: is the combination of AADs a valid option?
E. Aliot
Prevention of AF: will Dronedarone replace Amiodorone in the near future?
Prevention of AF: will Dronedarone replace Amiodorone in the near future?
R.L. Page
Atrial-selective AADs and other new antiarrhythmic agents: where are we?
Atrial-selective AADs and other new antiarrhythmic agents: where are we?
P. Dorian
ACE-inhibitors and ARBs: how to explain the different results reported with different compounds?
ACE-inhibitors and ARBs: how to explain the different results reported with different compounds?
C. Jazra
Statins and Omega-3 PUFA for the prevention of AF: do they really work?
Statins and Omega-3 PUFA for the prevention of AF: do they really work?
14.30 - 16.30
Anti-thrombotic Therapy 1 - ANTITHROMBOTIC THERAPY – A PRACTICAL APPROACH
Anti-thrombotic Therapy 1 - ANTITHROMBOTIC THERAPY – A PRACTICAL APPROACH
B. Gorenek
The patient with coronary or peripheral artery disease who develops AF
The patient with coronary or peripheral artery disease who develops AF
A.L. Waldo
The patient who has diffi culty keeping within target INR range of 2-3
The patient who has diffi culty keeping within target INR range of 2-3
S. Lévy
The patient with acute stroke and palpitations
The patient with acute stroke and palpitations
17.00 - 19.00
Anti-thrombotic Therapy 2 - ANTITHROMBOTIC THERAPY: DIFFICULT MANAGEMENT SCENARIOS
Anti-thrombotic Therapy 2 - ANTITHROMBOTIC THERAPY: DIFFICULT MANAGEMENT SCENARIOS
A. Oto
The patient with CHADS2 score of 1: Warfarin or Aspirin?
The patient with CHADS2 score of 1: Warfarin or Aspirin?
F. Di Pede
The patient at high risk of stroke who presents with an acute coronary syndrome and/or requires angioplasty/stenting
The patient at high risk of stroke who presents with an acute coronary syndrome and/or requires angioplasty/stenting
S.J. Connolly
The patient at high risk of stroke who needs elective surgery or dental surgery
The patient at high risk of stroke who needs elective surgery or dental surgery
J.J. Blanc
The patient who undergoes an ablation - do we stop Warfarin?
The patient who undergoes an ablation - do we stop Warfarin?
G. Di Pasquale
The patient at high risk of stroke with a previous history of major bleeding
The patient at high risk of stroke with a previous history of major bleeding
06/10/2009
LIONEL ROOM
08.30 - 10.30
Atrial Fibrillation 2009 revisited - TECHNIQUES FOR ABLATION OF AF REVISITED
Atrial Fibrillation 2009 revisited - TECHNIQUES FOR ABLATION OF AF REVISITED
G.J. Gallinghouse
PV antrum isolation
PV antrum isolation
G. Stabile
Circumferential PV ablation
Circumferential PV ablation
Y.H. Kim
Box approach
Box approach
L. Calň
CFAEs ablation
CFAEs ablation
S. Willems
Linear lesions
Linear lesions
11.00 - 13.00
SOLAECE Corner 2 - VAGAL DENERVATION AS A TREATMENT FOR PAROXYSMAL AF
SOLAECE Corner 2 - VAGAL DENERVATION AS A TREATMENT FOR PAROXYSMAL AF
S.Y. Ho
Anatomy, location and function of left atrial ganglionated plexi
Anatomy, location and function of left atrial ganglionated plexi
W.M. Jackman
Neural mechanisms of paroxysmal atrial fibrillation
Neural mechanisms of paroxysmal atrial fibrillation
R.P. Horton
Vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia
Vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia
M. Scanavacca
Long-term results of atrial vagal denervation guided by evoked vagal reflex
Long-term results of atrial vagal denervation guided by evoked vagal reflex
J.C. Pachňn
Long-term results of “nests” ablation guided by spectral mapping in sinus rhythm
Long-term results of “nests” ablation guided by spectral mapping in sinus rhythm
14.30 - 16.30
Atrial Fibrillation 2009 revisited - CLINICAL OUTCOMES OF AF ABLATION
Atrial Fibrillation 2009 revisited - CLINICAL OUTCOMES OF AF ABLATION
A. Verma
Metanalysis of the results obtained with the different ablation techniques
Metanalysis of the results obtained with the different ablation techniques
L. Di Biase
Periprocedural complications: still the sword of Damocles of AF ablation?
Periprocedural complications: still the sword of Damocles of AF ablation?
S. Themistoclakis
Early recurrences of AF: incidence, mechanisms, clinical significance and treatment
Early recurrences of AF: incidence, mechanisms, clinical significance and treatment
L.W. Lo
Late and very late AF recurrences: what to do?
Late and very late AF recurrences: what to do?
17.00 - 19.00
Atrial Fibrillation 2009 revisited - CONTROVERSIES ON INDICATIONS TO AF ABLATION (1)
Atrial Fibrillation 2009 revisited - CONTROVERSIES ON INDICATIONS TO AF ABLATION (1)
A. Raviele
The desire of patients to stop anticoagulation is an acceptable indication to AF ablation - Pro
The desire of patients to stop anticoagulation is an acceptable indication to AF ablation - Pro
S. Lévy
The desire of patients to stop anticoagulation is an acceptable indication to AF ablation - Cons
The desire of patients to stop anticoagulation is an acceptable indication to AF ablation - Cons
J.E. Sánchez
Elderly patients may safely undergo AF ablation - Pro
Elderly patients may safely undergo AF ablation - Pro
E. Aliot
Elderly patients may safely undergo AF ablation - Cons
Elderly patients may safely undergo AF ablation - Cons
J. Kautzner
Patients with enlarged LA (> 50 mm) are not good candidates to PVI - Pro
Patients with enlarged LA (> 50 mm) are not good candidates to PVI - Pro
E. Bertaglia
Patients with enlarged LA (> 50 mm) are not good candidates to PVI - Cons
Patients with enlarged LA (> 50 mm) are not good candidates to PVI - Cons
07/10/2009
LIONEL ROOM
08.30 - 10.30
Atrial Fibrillation 2009 revisited - CONTROVERSIES ON INDICATIONS OF AF ABLATION (2)
Atrial Fibrillation 2009 revisited - CONTROVERSIES ON INDICATIONS OF AF ABLATION (2)
H. Kottkamp
Catheter ablation of AF should be first-line therapy in young patients with lone AF - Pro
Catheter ablation of AF should be first-line therapy in young patients with lone AF - Pro
G.L. Botto
Catheter ablation of AF should be first-line therapy in young patients with lone AF - Cons
Catheter ablation of AF should be first-line therapy in young patients with lone AF - Cons
L. Gianfranchi
Pill-in-the-pocket approach is superior to catheter ablation in patients with paroxysmal AF - Pro
Pill-in-the-pocket approach is superior to catheter ablation in patients with paroxysmal AF - Pro
T. Arentz
Pill-in-the-pocket approach is superior to catheter ablation in patients with paroxysmal AF - Cons
Pill-in-the-pocket approach is superior to catheter ablation in patients with paroxysmal AF - Cons
A. Natale
Catheter ablation should be preferred to ablate and pace therapy in drug refractory AF - Pro
Catheter ablation should be preferred to ablate and pace therapy in drug refractory AF - Pro
W.K. Shen
Catheter ablation should be preferred to ablate and pace therapy in drug refractory AF - Cons
Catheter ablation should be preferred to ablate and pace therapy in drug refractory AF - Cons
W.K. Shen
Catheter ablation should be preferred to ablate and pace therapy in drug refractory AF - Cons Part 2
Catheter ablation should be preferred to ablate and pace therapy in drug refractory AF - Cons Part 2
11.00 - 13.00
Atrial Fibrillation 2009 revisited - CONTROVERSIES ON AF ABLATION TECHNIQUES
Atrial Fibrillation 2009 revisited - CONTROVERSIES ON AF ABLATION TECHNIQUES
M. Hocini
Linear lesions are pro-arrhythmic and should be avoided in patients with longlasting persistent AF - Cons
Linear lesions are pro-arrhythmic and should be avoided in patients with longlasting persistent AF - Cons
R. Cappato
Linear lesions are pro-arrhythmic and should be avoided in patients with longlasting persistent AF - Pro
Linear lesions are pro-arrhythmic and should be avoided in patients with longlasting persistent AF - Pro
L. Calň
CAFEs ablation alone is sufficient to prevent AF - Pro
CAFEs ablation alone is sufficient to prevent AF - Pro
P. Adragao
CAFEs ablation alone is sufficient to prevent AF - Cons
CAFEs ablation alone is sufficient to prevent AF - Cons
L. Mont
Non-inducibility predicts long-term success of ablation in long-lasting persistent AF - Pro
Non-inducibility predicts long-term success of ablation in long-lasting persistent AF - Pro
R. De Ponti
Non-inducibility predicts long-term success of ablation in long-lasting persistent AF - Cons
Non-inducibility predicts long-term success of ablation in long-lasting persistent AF - Cons
14.30 - 16.30
Atrial Fibrillation 2009 revisited - CONTROVERSIES ON POST AF ABLATION FOLLOW-UP
Atrial Fibrillation 2009 revisited - CONTROVERSIES ON POST AF ABLATION FOLLOW-UP
S. Ernst
Patients with early recurrences of AF should undergo prompt redo procedure - Pro
Patients with early recurrences of AF should undergo prompt redo procedure - Pro
R. De Ponti
Patients with early recurrences of AF should undergo prompt redo procedure - Cons
Patients with early recurrences of AF should undergo prompt redo procedure - Cons
G. Hindricks
Prolonged electrocardiographic monitoring is needed in all patients after the initial 3-6 months post-ablation - Pro
Prolonged electrocardiographic monitoring is needed in all patients after the initial 3-6 months post-ablation - Pro
A. Corrado
Prolonged electrocardiographic monitoring is needed in all patients after the initial 3-6 months post-ablation - Cons
Prolonged electrocardiographic monitoring is needed in all patients after the initial 3-6 months post-ablation - Cons
JD. Burkhardt
Long-term results of AF ablation are as good as short-term results - Pro
Long-term results of AF ablation are as good as short-term results - Pro
D.L. Packer
Long-term results of AF ablation are as good as short-term results - Cons
Long-term results of AF ablation are as good as short-term results - Cons
04/10/2009
ARAZZI ROOM
08.30 - 10.30
Venice Chart - Consensus Document on VT/VF Ablation - VENTRICULAR ARRHYTHMIAS: GENERAL ASPECTS
Venice Chart - Consensus Document on VT/VF Ablation - VENTRICULAR ARRHYTHMIAS: GENERAL ASPECTS
J. Farré
Classification of ventricular arrhythmias
Classification of ventricular arrhythmias
R. De Ponti
Clinical presentation and prognosis
Clinical presentation and prognosis
D.S. Cannom
Socioeconomic issues and impact on the healthcare system
Socioeconomic issues and impact on the healthcare system
D. Callans
Epidemiology of VT/VF and sudden death
Epidemiology of VT/VF and sudden death
11.00 - 13.00
Venice Chart - Consensus Document on VT/VF Ablation - ANATOMY OF RIGHT/LEFT VENTRICLES IN HEALTH AND DISEASES ASSOCIATED WITH VENTRICULAR ARRHYTHMIAS
Venice Chart - Consensus Document on VT/VF Ablation - ANATOMY OF RIGHT/LEFT VENTRICLES IN HEALTH AND DISEASES ASSOCIATED WITH VENTRICULAR ARRHYTHMIAS
S.Y. Ho
Anatomy of right/left ventricles in normal individuals
Anatomy of right/left ventricles in normal individuals
K. Soejima
Macroscopic and histological changes in post-infarction pts with VT/VF
Macroscopic and histological changes in post-infarction pts with VT/VF
A.C. Van der Wal
Dilated and hypertrophic cardiomyopathy associated with VT/VF: what does the pathologist fi nd at the anatomical table?
Dilated and hypertrophic cardiomyopathy associated with VT/VF: what does the pathologist fi nd at the anatomical table?
14.30 - 16.30
Venice Chart - Consensus Document on VT/VF Ablation - PATHOPHYSIOLOGY AND MECHANISMS OF VT/VF IN DIFFERENT CLINICAL SITUATIONS
Venice Chart - Consensus Document on VT/VF Ablation - PATHOPHYSIOLOGY AND MECHANISMS OF VT/VF IN DIFFERENT CLINICAL SITUATIONS
P.S. Chen
Mechanisms of VT/VF: what have we learned from experimental models?
Mechanisms of VT/VF: what have we learned from experimental models?
M. Scheinman
Re-entry, focal activity, triggered activity: what is wrong in the heart electricity?
Re-entry, focal activity, triggered activity: what is wrong in the heart electricity?
Y. Iesaka
The electrogenetic mechanisms of idiopathic VT
The electrogenetic mechanisms of idiopathic VT
C. Napolitano
The genetic background and mechanisms of arrhythmias in hereditary arrhythmogenic syndromes
The genetic background and mechanisms of arrhythmias in hereditary arrhythmogenic syndromes
J. Almendral
Patients with structural heart disease: what is responsible for sustained ventricular arrhythmias?
Patients with structural heart disease: what is responsible for sustained ventricular arrhythmias?
17.00 - 18.00
Opening Ceremony
Opening Ceremony
O. Lamanna
Greetings of Political Authorities
Greetings of Political Authorities
S. Rocco
Welcome Address
Welcome Address
A. Raviele, A. Natale
President Address
President Address
R.L. Page
Greetings of the Scientific Societies Representatives
Greetings of the Scientific Societies Representatives
A. Auricchio
Greetings of the Scientific Societies Representatives
Greetings of the Scientific Societies Representatives
W.L. Lo
Greetings of the Scientific Societies Representatives
Greetings of the Scientific Societies Representatives
R. Cappato
Greetings of the Scientific Societies Representatives
Greetings of the Scientific Societies Representatives
C.P. Lau
Greetings of the Scientific Societies Representatives
Greetings of the Scientific Societies Representatives
W. Zareba
Greetings of the Scientific Societies Representatives
Greetings of the Scientific Societies Representatives
Y. Nakazato
Greetings of the Scientific Societies Representatives
Greetings of the Scientific Societies Representatives
A. Revishvili
Greetings of the Scientific Societies Representatives
Greetings of the Scientific Societies Representatives
L. Molina
Greetings of the Scientific Societies Representatives
Greetings of the Scientific Societies Representatives
M.M. Gulizia
Greetings of the Scientific Societies Representatives
Greetings of the Scientific Societies Representatives
M. Di Biase
Greetings of the Scientific Societies Representatives
Greetings of the Scientific Societies Representatives
A. Biffi
Greetings of the Scientific Societies Representatives
Greetings of the Scientific Societies Representatives
18.00 - 18.15
Lecture
Lecture
A.J. Moss
Prevention of sudden death and heart failure: lessons from the MADIT Trials
Prevention of sudden death and heart failure: lessons from the MADIT Trials
18.15 - 18.30
Lecture
Lecture
J. Brugada
Brugada syndrome: state of the art on diagnosis, prognosis and therapy
Brugada syndrome: state of the art on diagnosis, prognosis and therapy
05/10/2009
ARAZZI ROOM
08.30 - 10.30
Venice Chart - Consensus Document on VT/VF Ablation - ECG FEATURES OF VT/VF AS EXPRESSION OF THE UNDERLYING MECHANISM AND SITE OF ORIGIN
Venice Chart - Consensus Document on VT/VF Ablation - ECG FEATURES OF VT/VF AS EXPRESSION OF THE UNDERLYING MECHANISM AND SITE OF ORIGIN
F. Marchlinski
The ECG in the different forms of idiopathic VT
The ECG in the different forms of idiopathic VT
J. Brugada
The ECG in Brugada syndrome and other arrhythmogenic hereditary syndromes
The ECG in Brugada syndrome and other arrhythmogenic hereditary syndromes
R. Schimpf
The ECG in ARVC/D
The ECG in ARVC/D
F. Bogun
The ECG to identify the site of origin of post-infarction VT
The ECG to identify the site of origin of post-infarction VT
11.00 - 13.00
Venice Chart - Consensus Document on VT/VF Ablation - PRE- AND INTRA- PROCEDURAL MANAGEMENT FOR VT/VF ABLATION
Venice Chart - Consensus Document on VT/VF Ablation - PRE- AND INTRA- PROCEDURAL MANAGEMENT FOR VT/VF ABLATION
K.H. Kuck
Hospital facilities and personnel requirements
Hospital facilities and personnel requirements
A. Corrado
Pre-ablation management: anticoagulation and other drugs
Pre-ablation management: anticoagulation and other drugs
K. Soejima
Transesophageal echocardiography and other imaging investigations
Transesophageal echocardiography and other imaging investigations
C. Tondo
Intraprocedural management including anticoagulation, sedation/anaesthesia and LV mechanical assistance
Intraprocedural management including anticoagulation, sedation/anaesthesia and LV mechanical assistance
13.00 - 14.30
Boston Scientific Celebration Session - 1984-2009: CELEBRATION OF THE FIRST 25 YEARS OF ICD THERAPY
Boston Scientific Celebration Session - 1984-2009: CELEBRATION OF THE FIRST 25 YEARS OF ICD THERAPY
14.30 - 16.30
Venice Chart - Consensus Document on VT/VF Ablation - MAPPING METHODS FOR VT/VF ABLATION
Venice Chart - Consensus Document on VT/VF Ablation - MAPPING METHODS FOR VT/VF ABLATION
M. Scanavacca
Endocardial vs epicardial approach
Endocardial vs epicardial approach
W.G. Stevenson
Mapping of stable VT: point by point activation mapping and entrainment mapping
Mapping of stable VT: point by point activation mapping and entrainment mapping
D. Callans
Mapping of unstable VT: multielectrode catheter mapping, substrate mapping and pacemapping
Mapping of unstable VT: multielectrode catheter mapping, substrate mapping and pacemapping
H. Kottkamp
Combined methods: traditional activation mapping plus substrate mapping
Combined methods: traditional activation mapping plus substrate mapping
P. Jaďs
VT ablation targetting late potential in patients with structural heart disease
VT ablation targetting late potential in patients with structural heart disease
17.00 - 19.00
Venice Chart - Consensus Document on VT/VF Ablation - IMAGING TOOLS, ENERGY SOURCES AND CATHETERS FOR VT/ VF ABLATION
Venice Chart - Consensus Document on VT/VF Ablation - IMAGING TOOLS, ENERGY SOURCES AND CATHETERS FOR VT/ VF ABLATION
R.J. Schilling
MRI and CT scan: when and why should they be performed
MRI and CT scan: when and why should they be performed
A. Al-Ahmad
ICE: what is its adjunct value?
ICE: what is its adjunct value?
J.E. Sánchez
Standard RF catheters: what is the outcome?
Standard RF catheters: what is the outcome?
W.M. Jackman
Cooled RF catheters: risk/benefi t ratio
Cooled RF catheters: risk/benefi t ratio
06/10/2009
ARAZZI ROOM
08.30 - 10.30
Venice Chart - Consensus Document on VT/VF Ablation - ABLATION OF VT/VF IN PATIENTS WITH STRUCTURAL HD: TECHNIQUES AND RESULTS
Venice Chart - Consensus Document on VT/VF Ablation - ABLATION OF VT/VF IN PATIENTS WITH STRUCTURAL HD: TECHNIQUES AND RESULTS
P. Della Bella
Post-myocardial infarction
Post-myocardial infarction
K. Soejima
Non-ischemic dilated cardiomyopathy
Non-ischemic dilated cardiomyopathy
A. Verma
Arrhythmogenic RV cardiomyopathy/dysplasia
Arrhythmogenic RV cardiomyopathy/dysplasia
J. Hebe
Repaired congenital heart disease
Repaired congenital heart disease
J. Sra
Bundle brunch reentrant VT, others
Bundle brunch reentrant VT, others
11.00 - 13.00
Venice Chart - Consensus Document on VT/VF Ablation - ABLATION OF VT/VF IN PATIENTS WITHOUT STRUCTURAL HD: TECHNIQUES AND RESULTS
Venice Chart - Consensus Document on VT/VF Ablation - ABLATION OF VT/VF IN PATIENTS WITHOUT STRUCTURAL HD: TECHNIQUES AND RESULTS
N. Boyle
RVOT tachycardia and pulmonary artery VT
RVOT tachycardia and pulmonary artery VT
J.D. Burkhardt
LVOT tachycardia, aortic cusp VT and mitral annulus VT
LVOT tachycardia, aortic cusp VT and mitral annulus VT
R. Cappato
LV fascicular tachycardia
LV fascicular tachycardia
A. Natale
Polymorphic VT, idiopathic VF
Polymorphic VT, idiopathic VF
13.00 - 14.30
MSD Luncheon Panel - PHARMACOLOGIC OR DIRECT CURRENT CARDIOVERSION? A GLIMPSE INTO THE FUTURE
MSD Luncheon Panel - PHARMACOLOGIC OR DIRECT CURRENT CARDIOVERSION? A GLIMPSE INTO THE FUTURE
M.Santini
Burden of Atrial Fibrillation, Importance of Cardioversion in the Management of Appropriate Patients
Burden of Atrial Fibrillation, Importance of Cardioversion in the Management of Appropriate Patients
J.Y. Le Heuzey
Pharmacologic cardioversion in 2009
Pharmacologic cardioversion in 2009
D. Roy
A look into the future of cardioversion
A look into the future of cardioversion
C. Torp-Pedersen
Panel discussion: pharmacologic versus direct current cardioversion - today and in the future
Panel discussion: pharmacologic versus direct current cardioversion - today and in the future
M.Santini
Closing Remarks
Closing Remarks
14.30 - 16.30
Venice Chart - Consensus Document on VT/VF Ablation - ACUTE AND PERIPROCEDURAL COMPLICATIONS OF VT/VF ABLATION
Venice Chart - Consensus Document on VT/VF Ablation - ACUTE AND PERIPROCEDURAL COMPLICATIONS OF VT/VF ABLATION
R. Ventura
Cardiac perforation/tamponade
Cardiac perforation/tamponade
A. Rossillo
Thromboembolic complications/stroke
Thromboembolic complications/stroke
D. Wilber
Coronary arteries injury, cardiac valve damage, acute pulmonary edema, phrenic nerve palsy and others
Coronary arteries injury, cardiac valve damage, acute pulmonary edema, phrenic nerve palsy and others
R.A. Schweikert
Complications of epicardial approach
Complications of epicardial approach
17.00 - 19.00
Venice Chart - Consensus Document on VT/VF Ablation - POST-ABLATION FOLLOW-UP MANAGEMENT
Venice Chart - Consensus Document on VT/VF Ablation - POST-ABLATION FOLLOW-UP MANAGEMENT
R.P. Horton
Treatment of recurrences: when to perform a redo procedure
Treatment of recurrences: when to perform a redo procedure
A. Verma
Which investigations and when?
Which investigations and when?
M.J. Schalij
Monitoring of LV function and optimization of hemodynamic status
Monitoring of LV function and optimization of hemodynamic status
07/10/2009
ARAZZI ROOM
08.30 - 10.30
Venice Chart - Consensus Document on VT/VF Ablation - CURRENT INDICATIONS TO VT/VF ABLATION, ALTERNATIVE THERAPEUTICAL OPTIONS, FUTURE PERSPECTIVES
Venice Chart - Consensus Document on VT/VF Ablation - CURRENT INDICATIONS TO VT/VF ABLATION, ALTERNATIVE THERAPEUTICAL OPTIONS, FUTURE PERSPECTIVES
E.N. Prystowsky
ACC/AHA/ESC Guidelines: are they applied in the real world? Should they be updated?
ACC/AHA/ESC Guidelines: are they applied in the real world? Should they be updated?
O. Alfieri
Surgery for VT: when is it justified?
Surgery for VT: when is it justified?
S.J. Connolly
ICD and antiarrhythmic drugs: the care for routine use
ICD and antiarrhythmic drugs: the care for routine use
D.L. Packer
Future tools and treatment options for VT/VF
Future tools and treatment options for VT/VF
11.00 - 13.00
HRS Corner 3 - ADVANCES IN CARDIOPULMONARY RESUSCITATION: IMPROVING OUTCOMES FROM ARREST
HRS Corner 3 - ADVANCES IN CARDIOPULMONARY RESUSCITATION: IMPROVING OUTCOMES FROM ARREST
D.P. Zipes
Epidemiology, prediction and prevention of cardiac arrest
Epidemiology, prediction and prevention of cardiac arrest
A. Capucci
Strategies for defibrillation: CPR fi rst, AEDs, life vests, new defibrillation science
Strategies for defibrillation: CPR fi rst, AEDs, life vests, new defibrillation science
R.L. Page
Home defibrillation: where are we and how to implement it?
Home defibrillation: where are we and how to implement it?
M. Link
Advances in life support, hypothermia, extracorporeal techniques
Advances in life support, hypothermia, extracorporeal techniques
T.L. Vanden Hoek
Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication
Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication
